Article Information
History
- November 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Sara Schumann1,*,
- Astrid Kaiser1,
- Ferdinando Nicoletti2,
- Katia Mangano2,
- Paolo Fagone2,
- Eduard van Wijk3,
- Yu Yan3,
- Petra Schulz1,
- Beate Ludescher1,
- Michael Niedermaier1,
- Joerg von Wegerer1,
- Pia Rauch4,
- Christian Setz4,
- Ulrich Schubert4 and
- Wolfgang Brysch1,*
- 1MetrioPharm Deutschland GmbH, Am Borsigturm 100, 13507 Berlin, Germany
- 2Dept. of Bio-medical Sciences, University of Catania, Via Androne, 8395124, Catania, Italy
- 3Meluna Research, Department of Biophotonics, Koppelsedijk 1A, 4191 LC Geldermalsen, The Netherlands
- 4Institute of Virology, Friedrich-Alexander University Erlangen-Nuernberg (FAU), Erlangen 91054, Germany
- 5MetrioPharm AG, Bleicherweg 10 8002 Zurich, Switzerland
- ↵*Correspondence: s.schumann{at}metriopharm.com; w.brysch{at}metriopharm.com
Posted November 04, 2020.
Immune modulating drug MP1032 with SARS-CoV-2 antiviral activity in vitro: A potential multi-target approach for prevention and early intervention treatment of COVID-19
